Literature DB >> 17048277

Sex difference in diffuse malignant peritoneal mesothelioma.

T D Yan1, E Popa, E A Brun, C A Cerruto, P H Sugarbaker.   

Abstract

BACKGROUND: Diffuse malignant peritoneal mesothelioma (DMPM) is rare and in the past has proved an invariably fatal disease. Female patients have been reported to have an improved survival outcome for reasons that are not understood.
METHODS: The survival of 34 men and 28 women who underwent cytoreduction and perioperative intraperitoneal chemotherapy for DMPM was compared. Twenty-five clinicopathological variables were subjected to univariate analysis.
RESULTS: The women had a 5-year survival rate of 63 per cent and median survival was not reached. The men had a 5-year survival rate of 42 per cent, with a median survival of 32 months (P = 0.045). Women had undergone more extensive previous surgery and had less extensive peritoneal involvement at the time of cytoreduction. Tumours in women more frequently showed a small nuclear size (30 microm or less) and the chromatin pattern was more often granular than clear.
CONCLUSION: Women with DMPM had better survival. This observation may be related to the favourable clinical and histopathological features associated with women.

Entities:  

Mesh:

Year:  2006        PMID: 17048277     DOI: 10.1002/bjs.5377

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  17 in total

1.  The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre.

Authors:  Lawson Ung; Terence C Chua; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-21       Impact factor: 4.553

2.  Malignant peritoneal mesothelioma presenting with persistent high fever.

Authors:  Li-ying Chen; Ling-xiu Huang; Jin Wang; Yi Qian; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2011-05       Impact factor: 3.066

Review 3.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

Review 4.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

5.  Malignant peritoneal mesothelioma presenting umbilical hernia and Sister Mary Joseph's nodule.

Authors:  Kota Tsuruya; Masashi Matsushima; Takayuki Nakajima; Mia Fujisawa; Katsuya Shirakura; Muneki Igarashi; Jun Koike; Takayoshi Suzuki; Tetsuya Mine
Journal:  World J Gastrointest Endosc       Date:  2013-08-16

6.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

Authors:  Francine Baumann; Erin Flores; Andrea Napolitano; Shreya Kanodia; Emanuela Taioli; Harvey Pass; Haining Yang; Michele Carbone
Journal:  Carcinogenesis       Date:  2014-11-07       Impact factor: 4.944

7.  Malignant peritoneal mesothelioma.

Authors:  Stine Munkholm-Larsen; Christopher Q Cao; Tristan D Yan
Journal:  World J Gastrointest Surg       Date:  2009-11-30

8.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

9.  Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma.

Authors:  Terence C Chua; Peng Yao; Javed Akther; Lawrence Young; Shisan Bao; Ushma Samaraweera; Tristan D Yan; David L Morris
Journal:  Pathol Oncol Res       Date:  2009-04-29       Impact factor: 3.201

10.  Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.

Authors:  Krishna Pillai; Mohammad Hossein Pourgholami; Terence C Chua; David Lawson Morris
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.